Quoin Pharmaceuticals (QNRX) announces that it has been granted Orphan Drug Designation, ODD, in Europe by the European Medicines Agency, EMA, for its lead product QRX003 in Netherton Syndrome. Orphan Drug Designation in Europe affords the Company incentive benefits including scientific advice on study protocols, various fee reductions and access to EU grants. If approved, QRX003 will be granted 10 years of market exclusivity in Europe for the treatment of Netherton Syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNRX:
- Quoin Pharmaceuticals Reports Q1 2025 Progress and Financials
- Quoin Pharmaceuticals Ltd – ADR trading resumes
- Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause
- Quoin Pharmaceuticals announces initial positive clinical data for QRX003
- Quoin Pharmaceuticals reports Q1 EPS ($6.50) vs ($38.73) last year